切换至 "中华医学电子期刊资源库"

中华肺部疾病杂志(电子版) ›› 2019, Vol. 12 ›› Issue (06) : 750 -753. doi: 10.3877/cma.j.issn.1674-6902.2019.06.017

短篇论著

肺腺癌患者中性粒细胞-淋巴细胞比率和血小板-淋巴细胞比率的临床价值
覃婉元1, 荆俊鹏2,()   
  1. 1. 530000 南宁,广西壮族自治区人民医院检验科
    2. 530000 南宁,广西壮族自治区妇幼保健院检验科
  • 收稿日期:2019-03-21 出版日期:2019-12-20
  • 通信作者: 荆俊鹏

Clinical value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in lung adenocarcinoma patients

Wanyuan Qin1, Junpeng Jing2()   

  • Received:2019-03-21 Published:2019-12-20
  • Corresponding author: Junpeng Jing
引用本文:

覃婉元, 荆俊鹏. 肺腺癌患者中性粒细胞-淋巴细胞比率和血小板-淋巴细胞比率的临床价值[J]. 中华肺部疾病杂志(电子版), 2019, 12(06): 750-753.

Wanyuan Qin, Junpeng Jing. Clinical value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in lung adenocarcinoma patients[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2019, 12(06): 750-753.

表1 NLR和PLR在肺肿瘤中的水平
图1 图A和B为肺腺癌ROC曲线,NLR ROC曲线下AUC面积为0.658,P=0.039,PLR ROC曲线下AUC面积为0.622,P=0.04,选取约登指数最大值处为cut-off值,NLR约登指数0.351,PLR约登指数为0.222,NLR和PLR的cut-off值分别为2.00和106.36,此时NLR的敏感性为0.605,特异性为0.746,PLR敏感性为0.659,特异性为0.563;图C和D为肺鳞癌ROC曲线,NLR ROC曲线下AUC面积为0.592,P=0.192,PLR曲线下AUC面积为0.589,P=0.207;图E和F为小细胞肺癌ROC曲线,NLR ROC曲线下AUC面积为0.602,P=0.150,PLR ROC曲线下AUC面积为0.595,P=0.182
表2 NLR和PLR与肺腺癌临床病理特征之间的关系
表3 NLR和PLR联合检测
1
Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64(1): 9-29.
2
Park DS, Hwang KE, Shim H, et al. Elevated survivin is associated with a poor response to chemotherapy and reduced survival in lung cancer with malignant pleural effusions[J]. Clin Exp Metastasis, 2012, 29(2): 83-89.
3
Stotz M, Pichler M, Absenger G, et al. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage Ⅲ colon cancer[J]. Br J Cancer, 2014, 110(2): 435-440.
4
Kundi H, Balun A, Cicekcioglu H, et al. Association between platelet to lymphocyte ratio and saphenous vein graft disease in patients with stable angina pectoris[J]. Anatol J Cardiol, 2016, 16(5): 349-353.
5
Asano Y, Kashiwagi S, Onoda N, et al. Predictive value of neutrophil/ lymphocyte ratio for efficacy of preoperative chemotherapy in triple-negative breast cancer[J]. Ann Surg Oncol, 2016, 23(4): 1104-1110.
6
Arigami T, Okumura H, Matsumoto M, et al. Analysis of the fibrinogen and neutrophil-lymphocyte ratio in esophageal squamous cell carcinoma: A promising blood marker of tumor progression and prognosis[J]. Medicine (Baltimore), 2015, 94(42): 1702.
7
马晓路,吴 炯,周 琰,等. 术前中性粒细胞/淋巴细胞比值对肝细胞肝癌根治性切除术后肿瘤早期复发的影响[J]. 检验医学,2016, 31(10): 863-868.
8
Zhao QT, Yang Y, Xu S, et al. Prognostic role of neutrophil to lymphocyte ratio in lung cancers: a meta-analysis including 7,054 patients[J]. Onco Targets Ther, 2015, 8: 2731-2738.
9
Li F, Hu H, Gu S, et al. Platelet to lymphocyte ratio plays an important role in prostate cancer's diagnosis and prognosis[J]. Int J Clin Exp Med, 2015, 8(7): 11746-11751.
10
Ozawa T, Tanaka J, Kiyomatsu T, et al. The preoperative platelet to lymphocyte ratio is a prognostic marker in patients with stage Ⅱ colorectal cancer [J]. Int J Colorectal Dis, 2015, 30(9): 1165-1171.
11
Fridlender ZG, Sun J, Kim S, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN[J]. Cancer Cell, 2009, 16(3): 183-194.
12
施爱军,吴晓柳,沈宗丽,等. 常见恶性肿瘤患者机体淋巴细胞亚群和活化T淋巴细胞的分析[J]. 国际检验医学杂志,2014, 35(20): 2758-2759.
13
张 静,骆剑明. 乳腺癌患者外周血淋巴细胞亚型和血小板水平及其临床意义[J]. 检验医学,2017, 32(11): 1004-1007.
14
Wang L, Liang D, Xu X, et al. The prognostic value of neutrophil to lymphocyte and platelet to lymphocyte ratios for patients with lung cancer[J]. Oncol Lett, 2017, 14(6): 6449-6456.
15
Kemal Y, Yucel I, Ekiz K, et al. Elevated serum neutrophil to lymphocyte and platelet to lymphocyte ratios could be useful in lung cancer diagnosis[J]. Asian Pac J Cancer Prev, 2014, 15(6): 2651-2654.
[1] 孙帼, 谢迎东, 徐超丽, 杨斌. 超声联合临床特征的列线图模型预测甲状腺乳头状癌淋巴结转移的价值[J]. 中华医学超声杂志(电子版), 2023, 20(07): 734-742.
[2] 李素娟, 丁文波, 武心萍, 邓学东. 被膜侵犯的甲状腺微小乳头状癌发生颈部淋巴结转移的超声相关危险因素分析[J]. 中华医学超声杂志(电子版), 2023, 20(04): 455-461.
[3] 陈启阳, 刘玉江, 刘金苹, 谭小蕖, 钱林学, 胡向东. 基于超声造影的预测模型对甲状腺乳头状癌颈中央区淋巴结转移的诊断价值[J]. 中华医学超声杂志(电子版), 2023, 20(04): 442-448.
[4] 刘星辰, 刘娟, 魏宝宝, 刘洁, 刘辉. XIAP与XAF1异常表达与卵巢癌的相关性分析[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 419-427.
[5] 李雄雄, 周灿, 徐婷, 任予, 尚进. 初诊导管原位癌伴微浸润腋窝淋巴结转移率的Meta分析[J]. 中华普通外科学文献(电子版), 2023, 17(06): 466-474.
[6] 樊逸隽, 杨枫, 王玮, 殷鹤英, 刘俊. 喉前淋巴结转移对甲状腺乳头状癌诊疗价值的研究进展[J]. 中华普通外科学文献(电子版), 2023, 17(04): 306-310.
[7] 李永浩, 高雪菲, 郭田田, 张进, 刘静. 峡部甲状腺乳头状癌手术方式的研究现状[J]. 中华普通外科学文献(电子版), 2023, 17(03): 225-230.
[8] 徐成, 王璐璐, 王少华. 洗脱液甲状腺球蛋白在甲状腺乳头状癌转移淋巴结中的应用[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 701-704.
[9] 袁育韬, 邢金琳, 谢克飞, 殷凯. CT征象及BRAFV600E基因突变与甲状腺乳头状癌中央区淋巴结转移的相关性[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 611-614.
[10] 汪沛, 倪蓓君, 元及, 宫为一, 范军. 卡瑞利珠单抗联合卡铂和培美曲塞治疗进展期肺腺癌的疗效及预后分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 511-513.
[11] 邱静, 黄庆. HJURP在肺腺癌组织中高表达并与患者不良预后相关性[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 495-499.
[12] 郝昭昭, 李多, 南岩东. 以肺磨玻璃结节为表现的肺腺癌发生机制研究进展[J]. 中华肺部疾病杂志(电子版), 2023, 16(03): 435-437.
[13] 王迪, 吕少诚, 黄金灿, 潘飞, 姜涛, 郎韧. 肺腺癌胰腺转移伴门静脉侵犯一例[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 457-460.
[14] 毛媛媛, 殷曰帅, 宓兵, 胡效坤. CT引导下经皮穿刺肺腺癌微波消融后致巨大空洞一例[J]. 中华介入放射学电子杂志, 2023, 11(03): 287-288.
[15] 李世浩, 李子豪, 董博, 吴春莉, 吴彬, 盛银良, 齐宇. 胞质分裂蛋白调节因子1对肺腺癌细胞迁移、侵袭和增殖的影响[J]. 中华胸部外科电子杂志, 2023, 10(03): 164-175.
阅读次数
全文


摘要